Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: TOL + interferon-alpha with or without vemurafenib in advanced melanoma
2013-000280-84Phase 2Completed
- Sponsor
- Finnish Melanoma Group
- Start
- Jul 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vemurafenib, interferon alfa and temozolomide + lomustine + vincristine in melanoma (2 arms), sponsored by Finnish Melanoma Group. Primary endpoint: Objective response rate. Started Jul 2013; status: completed.
02
Drugs
vemurafenibinterferon alfatemozolomide + lomustine + vincristine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-000280-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000280-84.